- Patia Diabetes is a biotechnology company dedicated to the development of biotechnological solutions for the prevention, diagnosis, and treatment of diabetes.
- Talde and Sinca Inbursa, of the Carlos Slim Foundation, since their entry into Patia, are promoting innovation in the Basque biotechnology industry and helping to fight the growing prevalence of type 2 diabetes in the Basque Country. The entry of the Basque Government will allow them to accelerate their growth.
The Basque Government, through Gestión de Capital Riesgo del País Vasco SGEIC, has formalized its entry into the biotech company Patia Diabetes with the aim of promoting research and development of advanced technological solutions for the prevention, diagnosis, and treatment of type 2 diabetes. This strategic alliance will enable Patia Diabetes to expand its operations and accelerate market arrival of its products. It will also contribute to scientific and technological progress in the treatment of diabetes, a chronic disease that affects an increasing number of people.
In recent years there has been an increase in the prevalence of diabetes (Incidence of diabetes mellitus and associated risk factors in the adult population of the Basque Country, Spain. Scientific Reports 2021). In turn, diabetes is a risk factor for the development and worsening of cardiovascular and other chronic diseases
It is important to highlight that the products developed by Patia Diabetes are already commercialized in the United States, the main market for this type of product, where they are already being reimbursed by the main health insurance companies, which demonstrates their effectiveness and recognized quality in the prevention and treatment of type 2 diabetes.